Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883050 | 0.93 | HTT (0.72) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL12767959 | 0.92 | HTT (0.75) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL4767798 | 0.89 | HTT (0.55) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL31196392 | 0.87 | EGLN3 (0.52) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL13952314 | 0.86 | TDP1 (0.61) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL21820621 | 0.83 | HTT (0.52) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL1581991 | 0.83 | CCR5 (0.52) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL31196390 | 0.83 | HTT (0.46) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL2544813 | 0.81 | LMNA (0.57) | HTTLMNATSHRNPSR1TDP1 | |
| SCHEMBL23499140 | 0.80 | TDP1 (0.54) | HTTLMNATSHRNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | HTT 1422/4885LMNA 1683/4885TSHR 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.